



NON-SMALL CELL LUNG CANCER (APRIL 2016): MOLECULAR ONCOLOGY TUMOR BOARDS COURSE REFERENCES

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. *N Engl J Med*. 2015; 373 (17): 1627-39. ([Full Text](#))

Brahmer J1, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Jul 9; 373(2): 123-35. ([Full Text](#))

Hellman MD, Creelan BC, Woo K, et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. *Annals of Oncology*. 2014; 25(4), iv429. ([Full Text](#))

Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2010 Jul; 11(7): 619-26. ([Full Text](#))

Huynh T, Morales-Oyarvide V, Uruga H, et al. PD-L1 Expression in Lung Adenocarcinomas Correlates with KRAS Mutations and Th1/Cytotoxic T Lymphocyte Microenvironment. *J Thorac Oncol*. 2015; 10: S198. ([Full Text](#))

Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*. 2015 Apr 30; 372(18): 1689-99. ([Full Text](#))

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012; 12(4): 252-64. ([Full Text](#))

Piotrowska Z, et al. Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy. *J Clin Oncol*. 32 :5s, 2014 (suppl; abstr 8053). ([View Abstract](#))

Ribas A. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. *Cancer Discov*. 2015; 5(9): 915-9. ([Full Text](#))

Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015; 348(6230): 124-8. ([View Abstract](#))

Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. *Sci Transl Med*. 2011; 3: 75ra26. ([Full Text](#))

Sholl LM, Aisner DL, Allen TC, et al. Programmed Death Ligand 1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2016 Jan 18. [Epub ahead of print]. ([Full Text](#))